Richard J Lessells
Overview
Explore the profile of Richard J Lessells including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
5194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Asare K, Lewis L, van der Molen J, Sookrajh Y, Khubone T, Moodley P, et al.
Open Forum Infect Dis
. 2023 Dec;
10(12):ofad583.
PMID: 38045558
Background: We aimed to compare clinical outcomes after viremia between dolutegravir vs efavirenz-based first-line antiretroviral therapy (ART) as evidence is lacking outside clinical trials in resource-limited settings. Methods: We conducted...
12.
Choga W, Kurusa Gasenna G, San J, Ookame T, Gobe I, Chand M, et al.
Int J Infect Dis
. 2023 Nov;
138:91-96.
PMID: 37952911
We investigated intra-host genetic evolution using two SARS-CoV-2 isolates from a fully vaccinated (primary schedule x2 doses of AstraZeneca plus a booster of Pfizer), >70-year-old woman with a history of...
13.
Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells R, et al.
medRxiv
. 2023 Jul;
PMID: 37461582
Background: Dolutegravir is now recommended for second-line anti-retroviral therapy (ART) in low- and middle-income countries. We compared outcomes with dolutegravir (DTG) versus the previous lopinavir/ritonavir (LPV/r) regimen in South Africa....
14.
Tegally H, Wilkinson E, Tsui J, Moir M, Martin D, Brito A, et al.
Cell
. 2023 Jul;
186(15):3277-3290.e16.
PMID: 37413988
The Alpha, Beta, and Gamma SARS-CoV-2 variants of concern (VOCs) co-circulated globally during 2020 and 2021, fueling waves of infections. They were displaced by Delta during a third wave worldwide...
15.
Evaluation of miniaturized Illumina DNA preparation protocols for SARS-CoV-2 whole genome sequencing
Pillay S, San J, Tshiabuila D, Naidoo Y, Pillay Y, Maharaj A, et al.
PLoS One
. 2023 Apr;
18(4):e0283219.
PMID: 37099540
The global pandemic caused by SARS-CoV-2 has increased the demand for scalable sequencing and diagnostic methods, especially for genomic surveillance. Although next-generation sequencing has enabled large-scale genomic surveillance, the ability...
16.
Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, et al.
Lancet HIV
. 2023 Mar;
10(5):e284-e294.
PMID: 37001536
Background: There are few data assessing the uptake of first-line dolutegravir among men and women living with HIV in low-income and middle-income countries, and subsequent clinical outcomes in non-trial settings....
17.
Maponga T, Jeffries M, Tegally H, Sutherland A, Wilkinson E, Lessells R, et al.
Clin Infect Dis
. 2023 Jan;
76(9):1702-1703.
PMID: 36718545
No abstract available.
18.
Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al.
Nat Commun
. 2022 Oct;
13(1):6057.
PMID: 36229444
No abstract available.
19.
Roshdy W, Khalifa M, San J, Tegally H, Wilkinson E, Showky S, et al.
Viruses
. 2022 Sep;
14(9).
PMID: 36146685
COVID-19 was first diagnosed in Egypt on 14 February 2020. By the end of November 2021, over 333,840 cases and 18,832 deaths had been reported. As part of the national...
20.
Dorward J, Naidoo J, Moodley P, Sookrajh Y, Samsunder N, Sayed F, et al.
J Acquir Immune Defic Syndr
. 2022 Sep;
91(2):189-196.
PMID: 36094486
Background: We aimed to evaluate the analytic performance of 3 rapid HIV viral load assays: the novel Xpert HIV-1 VL XC (Xpert XC), Xpert HIV-1 VL (Xpert VL), and m-PIMA...